Amneal Pharmaceuticals, Inc. (FRA:2DT)

Market Cap	3.22B
Revenue (ttm)	2.50B
Net Income (ttm)	5.03M
Shares Out	n/a
EPS (ttm)	0.01
PE Ratio	640.07
Forward PE	13.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	10.30
Previous Close	10.00
Day's Range	10.20 - 10.30
52-Week Range	5.70 - 11.10
Beta	n/a
RSI	58.19
Earnings Date	Mar 6, 2026

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalm...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 8,300
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2DT

Financial Performance

In 2024, Amneal Pharmaceuticals's revenue was $2.79 billion, an increase of 16.73% compared to the previous year's $2.39 billion. Losses were -$116.89 million, 39.2% more than in 2023.

Financial numbers in USD